J&J (JNJ) announces that the US FDA has granted Priority Review for subcutaneous amivantamab and hyaluronidase for adults with recurrent or metastatic head and neck squamous cell carcinoma

Priority Review is a procedural designation rather than an efficacy signal: it shortens the review clock and implies the agency sees a potentially meaningful advance over available therapy, but historically it tells the market little about approval odds beyond what the underlying data already show. The usual sequence from here is acceptance of the filing, a set action date, and then a binary decision, with the approval probability read-through driven by the pivotal trial results rather than the review tier itself. The more substantive angle is the subcutaneous reformulation angle: converting an intravenous oncology asset to subcutaneous administration has been a recurring lifecycle-management play across large pharma, used to defend franchises against competition and loss of exclusivity by shifting administration setting and adding patent life. J&J has prior form pursuing exactly this route with its oncology portfolio. Head and neck squamous cell carcinoma is also a label-expansion step for an asset whose established use sits elsewhere, so the commercial read is incremental indication breadth rather than a new franchise. For a mega-cap of this size, single-designation headlines of this kind have rarely moved the stock materially; the events that have mattered are the action date, the data behind the filing, and any advisory committee scheduling.